Moclobemide compared with second‐generation antidepressants in elderly people

@article{Vanna1990MoclobemideCW,
  title={Moclobemide compared with second‐generation antidepressants in elderly people},
  author={M. Vanna and J. Kummer and A. Agnoli and P. Gentili and A. Lorizio and R. Anand},
  journal={Acta Psychiatrica Scandinavica},
  year={1990},
  volume={82}
}
Two multicentre studies are described here; the first compared moclobemide with mianserin and the second with maprotiline, both in elderly patients with a DSM‐III diagnosis of major depressive episode. In the first study, 80 eligible patients were randomized to either moclobemide 300–500 mg or mianserin 75–125 mg per day for 4 weeks. Mean reduction in Hamilton Rating Scale for Depression (HRSD) score was 52% in both groups. The overall assessment of efficacy was good or very good for 60% of the… Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Efficacy and Tolerability of Moclobemide in Comparison with Placebo, Tricyclic Antidepressants, and Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients: A Clinical Overview
TLDR
Moclobemide is an effective and well-tolerated antidepressant for the treatment of elderly depressed patients and of similar efficacy to the TCAs and the more recently introduced SSRIs. Expand
A review of the reversible MAO‐A inhibitor moclobemide in geriatric patients
TLDR
A comparison of the relevant literature shows that moclobemide has advantages over other, classic, antidepressants because of better tolerability, fewer side effects and interactions, shorter latency of effect, and lower toxicity. Expand
Antidepressant Use in the Elderly
TLDR
Analysis of data from phase II and III trials showed that venlafaxine was comparably effective in the young and in a subset of over 350 elderly patients, and nefazodone and moclobemide have comparable efficacy in older and younger patients. Expand
Antidepressants and the elderly: Double‐blind trials 1987‐1992
We reviewed all double‐blind antidepressant trials reported between 1987 and 1992 in samples of people aged 55 years or more with a primary diagnosis of major or clinical depression. There was anExpand
Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
TLDR
With its efficacy against endogenous and nonendogenous depression, relatively rapid onset of antidepressant activity, and absence of carry-over effects on treatment withdrawal, moclobemide is likely to make an important contribution to the treatment of major depressive illness. Expand
Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings.
TLDR
Direct comparison data are insufficient for firm conclusions to be drawn about comparative efficacy, and Rigorously designed prospective studies on treatment outcome are urgently needed to provide robust data on which to base clinical recommendations for the treatment of depression in older patients. Expand
Antidepressants for depressed elderly.
TLDR
The review suggests that classical TCAs are associated with a higher withdrawal rate due to side effect experience, although these results must be interpreted with caution due to the relatively small size of the review and the heterogeneity of the drugs and patient populations. Expand
The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis.
TLDR
Elderly show no differences in antidepressant class outcomes, except SSRIs had a higher response rate than ATYPs, and there is little advantage for antidepressant classes over another in the aged. Expand
Pharmacotherapy of affective disorders in old age.
  • M. Tourigny-Rivard
  • Medicine
  • Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 1997
TLDR
Although the use of antidepressants in geriatric populations is more likely to be complicated by poorly tolerated side effects and drug interactions than in younger patients, this review should help clinicians use currently available medications to the best advantage of their geriatric patients. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 22 REFERENCES
Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.
TLDR
When the tolerability of moclobemide, as judged by reported and observed adverse events, is compared to that of placebo, it appears that only nausea is reported significantly more frequently with moclOBemide than with placebo; in particular the incidence of anticholinergic side effects was low with mclobemides and was significantly higher with the TCAs. Expand
A Comparative Clinical Trial of Mianserin (Norval®) and Amitriptyline in the Treatment of Depression in General Practice
TLDR
Both drugs proved equally effective in relieving the symptoms of primary depression but mianserin showed a reduced incidence of side-effects which was statistically significant. Expand
CLINICAL CHARACTERISTICS OF IMIPRAMINE-INDUCED ORTHOSTATIC HYPOTENSION
TLDR
The effects of imipramine hydrochloride on blood-pressure were examined in a prospective and a retrospective study and it was found that orthostatic hypotension is the commonest serious cardiovascular side-effect of imIPramine. Expand
Clinical Features and Management of Self-Poisoning with Newer Antidepressants
TLDR
There is as yet insufficient clinical data to comment on the specific toxicity of fluoxetine and fluvoxamine. Expand
The efficacy of antidepressant drugs. A review of research (1958-1972).
TLDR
An extensive review of published research on the efficacy of antidepressant medications is presented, which includes 146 double-blind studies on medications actively promoted in the United States as antidepressants during 1972 and lithium carbonate was not conclusively shown to be an effective antidepressant. Expand
Incidence of seizures with tricyclic and tetracyclic antidepressants.
TLDR
Data indicate that depressed patients taking the tetracyclic drug maprotiline are at risk for developing epileptic seizures. Expand
Tricyclic antidepressant overdose. A review.
TLDR
This article reviews epidemiologic, pharmacologic, and therapeutic information to provide a systematic approach to these potentially life-threatening overdoses of tricyclic antidepressant overdose. Expand
Clinical features and management of selfpoisoning with newer antidepressants
  • Med Toxic01 1986:
  • 1986
...
1
2
3
...